Development of Smart Food /Nutraceutical Solutions Dedicated to Cardiometabolic Disorders in Ageing (NutriAge)
NUTRI.AGE: DEVELOPMENT OF SMART FOOD/NUTRACEUTICAL SOLUTIONS DEDICATED TO CARDIOMETABOLIC DISORDERS IN AGEING
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Flavia Prodam, MD PhD
- Phone Number: +39-0321-660693
- Email: flavia.prodam@med.uniupo.it
Study Locations
-
-
-
Novara, Italy, 28100
- Recruiting
- SCDU Endocrinology. AOU Ospedale Maggiore della Carità
-
Contact:
- Flavia MD Prodam, MD PhD
- Phone Number: 0321660693
- Email: flavia.prodam@med.uniupo.it
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients of either gender, over 65 years of age, able to understand the protocol procedures.
- Known cardiovascular disease
- Prediabetes or type 2 diabetes mellitus with HbA1c < 7.0% on diet alone or metformin.
Exclusion Criteria:
- Age under 65
- Previous diagnosis of type 2 diabetes mellitus already undergoing drug therapy (except metformin)
- Contraindications such as allergy to product components
- Obesity secondary to diseases: genetic (Prader-Willi syndrome, Down syndrome); metabolic and endocrine (Cushing's syndrome, hypothyroidism)
- Endocrine or liver disease or clinical evidence of chronic disease or gastrointestinal disorders or malabsorption disorders
- History of adrenal adenoma or secondary arterial hypertension due to renal/adrenal causes
- Arterial hypertension treated with an ACE inhibitor or ARB
- Previous bariatric surgery
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Placebo
Participants will receive a placebo for 60 days to allow comparison of the results with those observed in the intervention arm.
Participants will take one placebo capsule once daily in the morning, on an empty stomach.
|
Participants will receive a probiotic for 60 days to allow comparison of the results with those observed in the placebo arm.
Participants will take one probiotic capsule once daily in the morning, on an empty stomach.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Blood glucose assessment with OGTT test and FGM
Time Frame: 4 months
|
Blood glucose and insulin tests at 0', 30', 60', 90', 120' minutes every 30 minutes Blood glucose monitoring at home
|
4 months
|
|
Pressure assessment
Time Frame: 4 months
|
Blood pressure is assessed during the visit at time 0 and after 60 days Filling out a blood pressure diary at home
|
4 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Anthropometric measurements
Time Frame: evaluation of weight and body composition through study completion, an average of 4 months
|
Weight is assessed in Kg with the use of the bioimpedance balance.
|
evaluation of weight and body composition through study completion, an average of 4 months
|
|
Anthropometric measurements
Time Frame: evaluation of weight and body composition through study completion, an average of 4 months
|
the height is measured in cm through a wall altimeter
|
evaluation of weight and body composition through study completion, an average of 4 months
|
|
Anthropometric measurements
Time Frame: evaluation of weight and body composition through study completion, an average of 4 months
|
the BMI (body mass index) is calculated by making the ratio of the weight to the square of the height.
normal weight is defined as 18.5-24.9
kg/m², overweight as 25.0-29.9
kg/m², and obesity as ≥30.0 kg/m
|
evaluation of weight and body composition through study completion, an average of 4 months
|
|
Anthropometric measurements
Time Frame: evaluation of weight and body composition through study completion, an average of 4 months
|
Waist, hip, arm, and calf circumferences are measured using an inelastic measuring tape.
Waist circumference is also assessed as an indicator of abdominal obesity and increased cardiometabolic risk, using the following reference cut-off values for European populations: ≥94 cm in men and ≥80 cm in women.
|
evaluation of weight and body composition through study completion, an average of 4 months
|
|
Adherence level to the Western diet with European Prospective Investigation into Cancer and Nutrition (EPIC) questionnaires
Time Frame: evaluation of weight and body composition through study completion, an average of 4 months
|
Assessed with the use of questionnaire.
EPIC is used for the bromatology evaluation of the diet, so there aren't scales but only indication about the macro and micronutrient composition.
This is a qualitative questionnaires and not quantitative.
|
evaluation of weight and body composition through study completion, an average of 4 months
|
|
Adherence level to the Western diet with 24h recall questionnaires
Time Frame: evaluation of weight and body composition through study completion, an average of 4 months
|
Assessed with the use of questionnaires.
24h recall questionnaire is used for the bromatology evaluation of the diet, so there aren't scales but only indication about the macro and micronutrient composition.
This is a qualitative questionnaires and not quantitative.
|
evaluation of weight and body composition through study completion, an average of 4 months
|
|
Advanced glycation end products quantification
Time Frame: evaluation of weight and body composition through study completion, an average of 4 months
|
AGE levels will be measured using skin fluorescence, using the "AGE reader mu" device (range from 1.3 to 5 level of AGEs respect to the patient's age)
|
evaluation of weight and body composition through study completion, an average of 4 months
|
|
Endogenous and exogenous AGEs plasma quantification
Time Frame: evaluation of weight and body composition through study completion, an average of 4 months
|
AGEs will also be assessed at the plasma level in free form (ELISA, fluorescence assay) or bound to hemoglobin (HbA1c clinical practice test), both measured in pg/mL
|
evaluation of weight and body composition through study completion, an average of 4 months
|
|
Soluble RAGEs plasma quantification
Time Frame: evaluation of weight and body composition through study completion, an average of 4 months
|
RAGEs will also be assessed at the plasma level in solule form (ELISA) measured in pg/mL
|
evaluation of weight and body composition through study completion, an average of 4 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Flavia Prodam, MD PhD, AOU Maggiore della Carita
Publications and helpful links
General Publications
- [1] Vadim N. GladyshevAging: progressive decline in fitness due to the rising deleteriome adjusted by genetic, environmental, and stochastic processes,06 April 2016 https://doi.org/10.1111/acel.12480. [2] Guo, J., Huang, X., Dou, L. et al. Aging and aging-related diseases: from molecular mechanisms to interventions and treatments. Sig Transduct Target Ther 7, 391 (2022). https://doi.org/10.1038/s41392-022-01251-0. [3] http://dati-anziani.istat.it/Index.aspx [4] https://www.salute.gov.it/portale/documentazione/p6_2_2_1.jsp?id=3074 [5] Ilse Bloom, Mark Edwards, Karen A. Jameson, Holly E. Syddall, Elaine Dennison, Catharine R. Gale, Janis Baird, Cyrus Cooper, Avan Aihie Sayer, Sian Robinson, Influences on diet quality in older age: the importance of social factors, Age and Ageing, Volume 46, Issue 2, March 2017, Pages 277-283, https://doi.org/10.1093/ageing/afw180 [6] https://doi.org/10.1093/ageing/afw180Ragonnaud, E., Biragyn, A. Gut microbiota as the key controllers of "healthy" aging of elderly people. Immun Ageing 18, 2 (2021). https://doi.org/10.1186/s12979-020-00213-w [7] Nuria Salazar, Lorena Valdés-Varela, Sonia González, Miguel Gueimonde & Clara G. de los Reyes-Gavilán (2017) Nutrition and the gut microbiome in the elderly, Gut Microbes, 8:2, 82- 97, DOI: 10.1080/19490976.2016.1256525 [8] Białecka-Dębek, A.; Granda, D.; Szmidt, M.K.; Zielińska, D. Gut Microbiota, Probiotic Interventions, and Cognitive Function in the Elderly: A Review of Current Knowledge. Nutrients 2021, 13, 2514. https://doi.org/10.3390/nu13082514 [9] Hutchinson, A.N.; Bergh, C.; Kruger, K.; Sűsserová, M.; Allen, J.; Améen, S.; Tingö, L. The Effect of Probiotics on Health Outcomes in the Elderly: A Systematic Review of Randomized, Placebo-Controlled Studies. Microorganisms 2021, 9, 1344. https://doi.org/10.3390/microorganisms9061344 [10] ALE, Elisa C.; BINETTI, Ana G. Role of probiotics, prebiotics, and synbiotics in the elderly: insights into their applications. Frontiers in Microbiology, 2021, 12: 631254. [11] Wu, H.; Chiou, J. Potential Benefits of Probiotics and Prebiotics for Coronary Heart Disease and Stroke. Nutrients 2021, 13, 2878. https://doi.org/10.3390/nu13082878 [12] Kiersnowska K, Jakubczyk A. Bioactive Peptides Obtained from Legume Seeds as New Compounds in Metabolic Syndrome Prevention and Diet Therapy. Foods. 2022 Oct 21;11(20):3300. doi: 10.3390/foods11203300. PMID: 37431048; PMCID: PMC9602117. [13] Alexander R, Khaja A, Debiec N, Fazioli A, Torrance M, Razzaque MS. Health-promoting benefits of lentils: Anti-inflammatory and anti-microbial effects. Curr Res Physiol. 2024 Mar 5;7:100124. doi: 10.1016/j.crphys.2024.100124. PMID: 38501131; PMCID: PMC10945126. [14] Rezvankhah A, Yarmand MS, Ghanbarzadeh B, Mirzaee H. Development of lentil peptides with potent antioxidant, antihypertensive, and antidiabetic activities along with umami taste. Food Sci Nutr. 2023 Feb 27;11(6):2974-2989. doi: 10.1002/fsn3.3279. PMID: 37324857; PMCID: PMC10261806. [15] Nicola Faccilongo, Giustina Pellegrini, Piermichele La Sala, Economia circolare e scarti nelle filiere agroalimentari: prima indagine esplorativa sullo stato dell'arte, in
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CE070/2025
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.